Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +2 more sources
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
Diabetes, Obesity and MetabolismAbstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a
Daniel Vincent O'Hara, Meg J. Jardine
openaire +3 more sources
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. [PDF]
Front Endocrinol (Lausanne), 2023 Objective Sarcopenia has been recognized as the third category of disabling complications in patients with type 2 diabetes mellitus(T2DM), in addition to micro- and macrovascular complications.
Zhang S, Qi Z, Wang Y, Song D, Zhu D.
europepmc +2 more sources
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. [PDF]
Front Endocrinol (Lausanne), 2023 Backgrounds The safety of different sodium-glucose transporter 2 (SGLT-2) inhibitors remains uncertain due to the lack of head-to-head comparisons. Methods This network meta-analysis (NMA) was performed to compare the safety of nine SGLT-2 inhibitors in ...
Li CX +8 more
europepmc +2 more sources
The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors. [PDF]
DiabetesThe early pathogenetic mechanism of diabetic retinopathy (DR) and its treatment remain unclear. Therefore, we used streptozotocin-induced diabetic mice to investigate the early pathogenic alterations in DR and the protective effect of sodium–glucose ...
Yamato M, Kato N, Yamada KI, Inoguchi T.
europepmc +2 more sources
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2022 Background Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk ...
Seung Eun Lee +5 more
doaj +1 more source
Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
Linchuang shenzangbing zazhi, 2023 Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule.
Feng Liu +3 more
doaj +1 more source
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. [PDF]
Front Pharmacol, 2021 Introduction: Minimally invasive extracorporeal circulation (MiECC) reduced inflammatory burden, leading to best clinical outcomes in patients treated with coronary artery bypass grafting (CABG).
Sardu C +11 more
europepmc +2 more sources
Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]
Australian Prescriber, 2020 Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire +2 more sources
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors [PDF]
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the
Janet B. McGill, Savitha Subramanian
openaire +3 more sources